• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Catalyst Biosciences Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket

    2/28/23 7:57:23 AM ET
    $ADMP
    $AHCO
    $APTX
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $ADMP alert in real time by email

    Gainers

    • Catalyst Biosciences Inc (NASDAQ:CBIO) rose 105% to $0.49 in pre-market trading. South Korea's GC Biopharma said it has signed an asset purchase agreement with Catalyst Biosciences to acquire 3 programs related to the orphan hematology disorders.
    • Intelligent Living Application Group Inc. (NASDAQ:ILAG) rose 40.3% to $1.74 in pre-market trading after the company announced plans to develop advanced smart home security devices.
    • Obseva SA (NASDAQ:OBSV) shares rose 24.4% to $0.12 in pre-market trading after gaining over 16% on Monday. ObsEva announced strategic reorganization to consolidate operations in Switzerland.
    • Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) rose 23.1% to $0.3244 in pre-market trading. Adamis Pharmaceuticals and DMK Pharmaceuticals announced agreement and plan of merger.
    • Mount Rainier Acquisition Corp (NASDAQ:RNER) rose 19.8% to $6.05 in pre-market trading. Mount Rainier Acquisition shares dropped 46% on Monday possibly after the company's general meeting was cancelled on Sunday.
    • Lion Group Holding Ltd. (NASDAQ:LGHL) rose 15.9% to $0.40 in pre-market trading after dropping 10% on Monday.
    • Progyny Inc (NASDAQ:PGNY) shares rose 14.6% to $35.62 in pre-market trading after the company reported better-than-expected Q4 results.
    • AIM ImmunoTech Inc (NYSE:AIM) rose 14.6% to $0.55 in pre-market trading after dropping over 7% on Monday. AIM ImmunoTech, last month, entered into a sponsored collaborative clinical research agreement with Erasmus MC and AstraZeneca.
    • Ocugen Inc (NASDAQ:OCGN) rose 11.7% to $1.09 in pre-market trading. Ocugen announced submission of investigational new drug application with the FDA to initiate Phase 1 clinical trial evaluating OCU200 for the treatment of diabetic macular edema.
    • Smart for Life Inc (NASDAQ:SMFL) shares rose 10.5% to $0.21 in pre-market trading after gaining over 7% on Monday.

    Losers

    • Aptinyx Inc (NASDAQ:APTX) shares fell 63.6% to $0.22 in pre-market trading after the company reported results from Phase 2 study of NYX-458 in cognitive impairment associated with Parkinson's disease and dementia with lewy bodies and issued pipeline and corporate update.
    • Verde Clean Fuels Inc (NASDAQ:VGAS) fell 18.8% to $10.00 in pre-market after dropping around 17% on Monday.
    • Adapthealth Corp (NASDAQ:AHCO) fell 18.3% to $17.95 in pre-market trading after the company posted a loss for the fourth quarter.
    • Lucira Health Inc (NASDAQ:LHDX) fell 14.7% to $0.43 in pre-market trading. Lucira Health shares jumped 264% on Monday after the company announced FDA authorization for its at-home combination COVID-19 & flu test.
    • Sera Prognostics Inc (NASDAQ:SERA) shares dropped 13.9% to $3.40 in pre-market trading after jumping 18% on Monday. The company recently announced top-line data from the AVERT PRETERM TRIAL.
    • NewtekOne Inc (NASDAQ:NEWT) fell 12.8% to $16.80 in pre-market trading following weaker-than-expected Q4 results.
    • COMSovereign Holding Corp (NASDAQ:COMS) fell 7.6% to $3.39 in pre-market trading after gaining around 10% on Monday. COMSovereign recently announced an 80% year-over-year reduction of outstanding secured debt.
    • Performance Shipping Inc (NASDAQ:PSHG) fell 7.4% to $2.50 in pre-market trading. Performance Shipping announced termination of at-the-market offering.
    • Smith Micro Software, Inc. (NASDAQ:SMSI) shares fell 6.9% to $1.48 in pre-market trading. Smith Micro Software shares dropped 36% on Monday after the company announced it received written notice of contract termination from a U.S.-based Tier 1 carrier customer for the company's family safety solution.
    • Milestone Scientific Inc (NYSE:MLSS) fell 6.4% to $0.71 in pre-market trading after surging 18% on Monday. Milestone Scientific announced 510(k) FDA clearance for the use of CompuFlo® Epidural System in thoracic indications.

    Now Read This: Wall Street's Most Accurate Analysts Say Hold These 3 Tech Stocks Delivering High-Dividend Yields

    Get the next $ADMP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADMP
    $AHCO
    $APTX
    $CBIO

    CompanyDatePrice TargetRatingAnalyst
    Crescent Biopharma Inc.
    $CBIO
    1/28/2026$35.00Overweight
    Piper Sandler
    Crescent Biopharma Inc.
    $CBIO
    1/21/2026$35.00Buy
    Guggenheim
    Progyny Inc.
    $PGNY
    1/20/2026$30.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Progyny Inc.
    $PGNY
    1/8/2026$34.00Hold → Buy
    Truist
    Sera Prognostics Inc.
    $SERA
    12/15/2025$5.00Buy
    Jefferies
    Progyny Inc.
    $PGNY
    12/9/2025$29.00Overweight
    Barclays
    Progyny Inc.
    $PGNY
    11/12/2025$30.00Sector Weight → Overweight
    KeyBanc Capital Markets
    NewtekOne Inc.
    $NEWT
    9/15/2025$18.00Buy
    B. Riley Securities
    More analyst ratings

    $ADMP
    $AHCO
    $APTX
    $CBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AIM ImmunoTech Announces Closing of its Rights Offering

    OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) – AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – announced today the closing of its previously announced rights offering (the "Rights Offering"). The Rights Offering resulted in total subscriptions of approximately $1.8 million. Each right entitled the holder to purchase one unit ("Unit"), at a subscription price of $1,000 per Unit, consisting of one share of the Company's Series G Convertible Preferred Stock

    3/6/26 7:00:00 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Crescent Biopharma Announces Grants of Inducement Awards

    WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 45,675 shares of the Company's ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the "Inducement Plan"). The options were approved on March 5, 2026 and were material to each employee's acceptanc

    3/6/26 4:15:00 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Progyny, Inc. Executives to Participate in Upcoming Investor Conferences

    NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced that several members of its leadership team will participate in upcoming investor conferences in March, including the Leerink Partners Global Healthcare Conference, the Barclays Global Healthcare Conference, and the KeyBanc Capital Markets Healthcare Forum. At the Leerink Partners Global Healthcare Conference, Mark Livingston, Chief Financial Officer, will participate in a fireside chat on March 10, 2026, at 10:40 a.m. Eastern Time. At the Barclays Global Healthcare Conference, Pete Anevski, Chief Executive Officer, will participate in

    3/6/26 9:02:47 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $ADMP
    $AHCO
    $APTX
    $CBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lawrence Sandra Aj sold $3,042 worth of shares (1,560 units at $1.95), decreasing direct ownership by 8% to 18,033 units (SEC Form 4)

    4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

    3/6/26 7:25:13 PM ET
    $SERA
    Medical Specialities
    Health Care

    EVP, GC Swartz Allison covered exercise/tax liability with 339 shares and sold $10,506 worth of shares (599 units at $17.54), decreasing direct ownership by 1% to 88,941 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    3/6/26 4:36:37 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    CHIEF FINANCIAL OFFICER Livingston Mark S. covered exercise/tax liability with 339 shares, decreasing direct ownership by 0.39% to 87,338 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    3/6/26 4:35:02 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $ADMP
    $AHCO
    $APTX
    $CBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wolf Dale B bought $71,680 worth of shares (8,000 units at $8.96), increasing direct ownership by 8% to 104,235 units (SEC Form 4)

    4 - AdaptHealth Corp. (0001725255) (Issuer)

    3/3/26 6:41:28 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    CLO and General Counsel Rew Richard W. Ii bought $44,550 worth of shares (5,000 units at $8.91), increasing direct ownership by 5% to 107,097 units (SEC Form 4)

    4 - AdaptHealth Corp. (0001725255) (Issuer)

    2/27/26 4:01:18 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    Director Fairmount Funds Management Llc bought $18,237,600 worth of Ordinary Shares (1,360,000 units at $13.41) (SEC Form 4)

    4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)

    12/8/25 4:30:15 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AHCO
    $APTX
    $CBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Crescent Biopharma with a new price target

    Piper Sandler initiated coverage of Crescent Biopharma with a rating of Overweight and set a new price target of $35.00

    1/28/26 7:10:21 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Crescent Biopharma with a new price target

    Guggenheim initiated coverage of Crescent Biopharma with a rating of Buy and set a new price target of $35.00

    1/21/26 8:54:45 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Progyny upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Progyny from Mkt Perform to Mkt Outperform and set a new price target of $30.00

    1/20/26 8:45:21 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $ADMP
    $AHCO
    $APTX
    $CBIO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZIMHI issued to ADAMIS PHARMS CORP

    Submission status for ADAMIS PHARMS CORP's drug ZIMHI (ORIG-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 10/15/2021. Application Category: NDA, Application Number: 212854, Application Classification: Type 5 - New Formulation or New Manufacturer

    10/18/21 11:55:40 AM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SYMJEPI issued to ADAMIS PHARMS CORP

    Submission status for ADAMIS PHARMS CORP's drug SYMJEPI (SUPPL-12) with active ingredient EPINEPHRINE has changed to 'Approval' on 06/29/2021. Application Category: NDA, Application Number: 207534, Application Classification: Labeling

    6/30/21 5:11:48 AM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AHCO
    $APTX
    $CBIO
    SEC Filings

    View All

    AIM ImmunoTech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - AIM ImmunoTech Inc. (0000946644) (Filer)

    3/6/26 5:15:32 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Sera Prognostics Inc.

    144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    3/6/26 4:30:10 PM ET
    $SERA
    Medical Specialities
    Health Care

    SEC Form 10-K filed by Smith Micro Software Inc.

    10-K - SMITH MICRO SOFTWARE, INC. (0000948708) (Filer)

    3/5/26 5:08:37 PM ET
    $SMSI
    Computer Software: Prepackaged Software
    Technology

    $ADMP
    $AHCO
    $APTX
    $CBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Progyny Inc.

    SC 13G/A - Progyny, Inc. (0001551306) (Subject)

    12/6/24 10:11:35 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Smith Micro Software Inc.

    SC 13G/A - SMITH MICRO SOFTWARE, INC. (0000948708) (Subject)

    11/15/24 8:30:55 AM ET
    $SMSI
    Computer Software: Prepackaged Software
    Technology

    $ADMP
    $AHCO
    $APTX
    $CBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Smith Micro Announces Tim Huffmyer to Succeed Bill Smith as President and CEO

    Smith Micro Software, Inc. (NASDAQ:SMSI) today announced that it has named current Chief Operating Officer and Chief Financial Officer Tim Huffmyer to serve as Smith Micro's next President and Chief Executive Officer. Huffmyer will assume the role from Bill Smith, who has been appointed to the role of Executive Chairman. The changes will take effect on March 31, 2026 and follow leadership succession planning led by Smith and the Company's Board of Directors. "This planned leadership transition reflects the Board's ongoing succession planning and commitment to continuity in leadership and disciplined execution," said Smith. "With Tim's demonstrated strategic, financial and operational perf

    3/4/26 4:03:00 PM ET
    $SMSI
    Computer Software: Prepackaged Software
    Technology

    Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

    MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). "Mrs. Johnson-Greene's diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen's CFO," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of three Biologics License Applications (BLAs) this

    2/9/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    $ADMP
    $AHCO
    $APTX
    $CBIO
    Financials

    Live finance-specific insights

    View All

    Performance Shipping Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2025

    ATHENS, Greece, March 04, 2026 (GLOBE NEWSWIRE) -- Performance Shipping Inc. (NASDAQ:PSHG) ("we" or the "Company"), a global shipping company specializing in the ownership of tanker vessels, today reported net income of $7.6 million for the fourth quarter of 2025, compared to a net income of $9.7 million for the same period in 2024. Earnings per share, basic and diluted, for the fourth quarter of 2025 were $0.57 and $0.19, respectively. Revenue was $26.2 million ($24.6 million net of voyage expenses) for the fourth quarter of 2025, compared to $21.7 million ($19.8 million net of voyage expenses) for the same period in 2024. This increase was mainly attributable to the increase in ownershi

    3/4/26 9:27:00 AM ET
    $PSHG
    Marine Transportation
    Consumer Discretionary

    SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS ON MARCH 18, 2026

    SALT LAKE CITY, March 4, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report fourth quarter and fiscal year 2025 financial results on Wednesday March 18, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

    3/4/26 8:05:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    Progyny, Inc. Announces Fourth Quarter 2025 Results

    Reports Revenue of $318.4 Million, Reflecting Fourth Quarter Growth of 6.7% and 10% for the Full YearGenerated Record $210.2 Million in Full Year Operating Cash FlowReturned Value to Shareholders Through Repurchase of Approximately 6.5 Million Shares To Date Under Recent AuthorizationIssues Financial Guidance for 2026, Reflecting Tenth Consecutive Year of Revenue Growth NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three- and twelve-month periods ended December 31, 2025 ("the fourth quarter of 2025" and "the full year", resp

    2/26/26 4:01:00 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care